ライフサイエンスコーパス: fatigue

1 ymptoms is paramount, including pruritus and fatigue.

2 ains one of the most challenging problems in fatigue.

3 placebo in patients with multiple sclerosis fatigue.

4 inside the SR, thus contributing to myogenic fatigue.

5 se effects included cognitive complaints and fatigue.

6 h numbers of monitoring alarms lead to alarm fatigue.

7 e regions changes as a function of cognitive fatigue.

8 ns characterized by unexplained debilitating fatigue.

9 n and an inability to exercise due to muscle fatigue.

10 pain, weakness, intolerance to exercise, and fatigue.

11 ese areas changes as a function of cognitive fatigue.

12 ver, followed by cough, myalgia, chills, and fatigue.

13 maximize clinical utility and minimize alert fatigue.

14 der, mood disorders, GI problems and chronic fatigue.

15 match metabolic demand and prevent premature fatigue.

16 ible urticarial rash, arthralgia, fever, and fatigue.

17 in, breathlessness, nausea and vomiting, and fatigue.

18 sal association between low 25OHD-levels and fatigue.

19 abdominal pain, accompanied by sweating and fatigue.

20 association between hippocampal atrophy and fatigue.

21 en any individual 25OHD-reducing variant and fatigue.

22 f nitric oxide and can delay skeletal muscle fatigue.

23 with improvement in hypothyroid symptoms or fatigue.

24 r shift workers (p<0.001) had higher chronic fatigue.

25 city, poor physical function and symptoms of fatigue.

26 the Social and Domestic Survey, and chronic fatigue.

27 increased sleepiness and increased levels of fatigue.

28 es of nursing such as burnout and compassion fatigue.

29 lt in palpitations, dyspnea, presyncope, and fatigue.

30 luation of prospective physical effort while fatigued.

31 mg once daily vs 5% [9/186] for placebo) and fatigue (1% [1/93] for 10 mg once daily to 10% [9/91] fo

32 d neutrophil count (22 [5%] vs 16 [4%]), and fatigue (17 [4%] vs 15 [3%]).

33 and CaboNivoIpi, respectively, and included fatigue (17% and 10%, respectively), diarrhea (4% and 7%

34 8 to 3.87), chest pain (0.4, -2.13 to 2.93), fatigue (2.2, -0.38 to 4.78), appetite loss (1.2, -1.27

35 ng injection site reactions (62% to 72%) and fatigue (21% to 24%).

36 in the bortezomib and dexamethasone group), fatigue (26 [13%] vs two [1%]), anaemia (31 [16%] vs 20

37 ts were nausea (in 31 [63%] of 49 patients), fatigue (26 [53%]), diarrhoea (17 [35%]), and vomiting (

38 grade 4) and non-haematological toxicity was fatigue (28 [37%] patients; none had grade 3 or grade 4)

39 of all patients was frail, 65% suffered from fatigue, 28% and 26% from symptoms of anxiety and depres

40 [-4.57 to -1.60] vs -3.5 [-5.68 to -1.29]), fatigue (-3.0 [-4.53 to -1.50] vs -5.2 [-7.45 to -2.98])

41 events were pyrexia (36 [41%] patients) and fatigue (31 [36%]).

42 %) adverse events, regardless of cause, were fatigue (31 [42%]; two [3%] grade >=3), nausea (25 [34%]

43 d in 93% of patients, most commonly (>= 25%) fatigue (33.3%), nausea/vomiting (33.3%), and infusion-r

44 d non-haematological adverse events included fatigue (34 [6%] of 527 patients in the VRd group vs 29

45 common treatment-related adverse events were fatigue (58%), diarrhea (52%), hypertension (47%), and h

46 Most common adverse events included fatigue (62%), and upper respiratory tract infection (42

47 ated, with pruritus (149 [77%] patients) and fatigue (63 [33%]) being the most common adverse events.

48 events were diarrhea (12%), pruritus (12%), fatigue (7%), and pyrexia (7%).

49 sensory neuropathy (79%), neutropenia (76%), fatigue (74%), and nausea (71%).

50 Fatigue (83%) and hypertension (75%) were the most commo

51 ed more subjective AEs than men per quarter (fatigue: 86.98 more per quarter, P=0.035; subjective mus

52 nical toxicity mainly consisted of grade 1/2 fatigue (87.1%) and grade 1 nausea or vomiting (67.7%) d

53 ematuria, change in bowel habit, hoarseness, fatigue, abdominal pain, lower abdominal pain, weight lo

54 t health and wellbeing (increased accidents, fatigue, absenteeism) but can be perceived as beneficial

55 veolar concentration of volatile anesthetic, fatigue, active time, and respiratory function.

56 the female diaphragm is more susceptible to fatigue after inspiratory loading under acute hypoxic co

57 Rash, peripheral neuropathy, fatigue, alopecia, and nausea were the most common treat

58 y was to assess the prevalence of compassion fatigue among Chinese nurses, and to explore the factors

59 c liver disease linked to symptoms including fatigue and altered mood/cognition, indicating that chro

60 Insomnia, fatigue and appetite changes had lower centrality values

61 ortness of breath, chest pain and pronounced fatigue and are at risk of developing lung fibrosis or i

62 r to placebo in improving multiple sclerosis fatigue and caused more frequent adverse events.

63 In paclitaxel-treated mice, increased fatigue and decreased cognitive performance occurred in

64 face and tear film that leads to discomfort, fatigue and disturbance in vision.

65 a therapeutic opportunity to improve muscle fatigue and dysfunction in this population.

66 hene-only devices are limited in size due to fatigue and fracture of suspended graphene membranes.

67 er intravenous iron supplementation improves fatigue and general health in non-anemic repeat adult bl

68 s with low iron stores, yet had no effect on fatigue and general well-being.

69 atients with multiple sclerosis who reported fatigue and had a Modified Fatigue Impact Scale (MFIS) s

70 identify nurses' vulnerability to compassion fatigue and implement targeted strategies to reduce nurs

71 We show that incorporating fatigue and long-term behavior change can reconcile the

72 remained a significant predictor of chronic fatigue and lower satisfaction with time for daily tasks

73 the treatment after one month, due to severe fatigue and mental confusion; the symptoms disappeared i

74 de; the most frequently reported events were fatigue and musculoskeletal events.

75 ealth consequences to the workers related to fatigue and other factors.

76 to their outstanding high temperature creep, fatigue and oxidation resistance.

77 at 6, 12, and 24 months after radiotherapy: fatigue and physical functioning (EORTC QLQ-C30); cosmet

78 Patients suffer from severe fatigue and postexertional malaise.

79 n, general discomfort, polydipsia, polyuria, fatigue and recent weight loss of 10 kg.

80 Improvement in fatigue and sexual function did not differ between group

81 Spasticity can cause pain, fatigue and sleep disturbances; restrict daily activitie

82 ditions but could eventually lead to greater fatigue and stress of the muscle tissue.

83 this strategy could lead to increased muscle fatigue and symptom aggravation in the long term.

84 terations of neuronal responses that reflect fatigue and temporal acuity deficits.

85 gions that appear to be related to cognitive fatigue and that potentially comprise a "fatigue network

86 bear large chewing forces, resist mechanical fatigue and withstand wear over decades(2).

87 ienced grade >= 2 TEAEs of nausea, vomiting, fatigue, and asthenia.

88 Patients experience muscle pain, weakness, fatigue, and atrophy, but the underlying mechanisms are

89 r digitorum longus and soleus muscle forces, fatigue, and contractile kinetics in vitro, along with C

90 ding to dry cough, fever, myalgia, headache, fatigue, and diarrhea and can end up in interstitial pne

91 rointestinal symptoms, as well as headaches, fatigue, and dizziness.

92 mild-to-moderate pain at the injection site, fatigue, and headache.

93 ance (hyperphagia, weight gain, hypersomnia, fatigue, and leaden paralysis) and may moderate the anti

94 e most common AEs included myelosuppression, fatigue, and nausea/vomiting.

95 th cardiomyopathy, skeletal muscle weakness, fatigue, and other symptoms, probably all related to mit

96 thermal half-lives, photostationary states, fatigue, and quantum yields were determined.

97 nstipation, dizziness, vomiting, somnolence, fatigue, and sedation.

98 hown to improve depression symptom severity, fatigue, and sexual function in small studies in women n

99 terone improves depression symptom severity, fatigue, and sexual function in women with antidepressan

100 which are licensed with the Sleep, Activity, Fatigue, and Task Effectiveness (SAFTE(tm)) Alertness Sc

101 plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting.

102 , and other typical symptoms such as intense fatigue, anxiety and depression.

103 gnitive impairments, emotional problems, and fatigue are common among patients who have survived card

104 Sleep disturbance and fatigue are commonly reported among patients with Crohn'

105 wever, studies on Chinese nurses' compassion fatigue are scarce, especially large sampled, multi-cent

106 Nusinersen reduces fatigue as measured by the FSS in adult patients with 5q

107 ons, both healthy female and male diaphragms fatigue at a similar degree when matched for absolute di

108 vels: SF (n = 30, i.e. patients who reported fatigue at the latest >=2 assessments), RF (n = 31, i.e.

109 assessments), RF (n = 31, i.e. patients not fatigued at the latest assessment, but reported fatigue

110 hat diabetes impaired targeted remodeling in fatigued bone at every key stage, including increased ap

111 Besides, the concept of cognitive control fatigue bridges the functional consequences of excessive

112 tiple cognitive factors, such as arousal and fatigue, but it is unclear how these factors influence t

113 dry eye were generally lower than those for fatigue, but were similar to dry mouth and considerably

114 c phosphate (P(i) ) may contribute to muscle fatigue by precipitating calcium salts inside the sarcop

115 esized that CK-2066260 could mitigate muscle fatigue by reducing the energetic cost of muscle activat

116 Fatigue can be measured within the Fatigue Severity Scal

117 e, depression, cognition, self-rated health, fatigue, care satisfaction, home blood pressure monitori

118 r level of frailty (Clinical Frailty Scale), fatigue (Checklist Individual Strength-8), anxiety and d

119 ate in severity and most frequently included fatigue, chills, headache, myalgia, and pain at the inje

120 in more than half the participants included fatigue, chills, headache, myalgia, and pain at the inje

121 Insufficient sleep and resulting fatigue compromises personal safety, mission success, an

122 in 1 family, improvement in power, pain, and fatigue contributing to patients regaining their ability

123 atigue threshold of 800 J m(-2), because the fatigue-crack propagation at the interface requires a hi

124 Physical fatigue crucially influences our decisions to partake in

125 Fatigue damage in metals manifests itself as irreversibl

126 at objective performance, but not subjective fatigue, declined from the beginning to the end of the m

127 eries of experiments, we describe how muscle fatigue, defined as degradation of maximum force after e

128 zed that (1) OCC would exacerbate peripheral fatigue development and increase the rate of motor unit

129 C) to determine relationships between muscle fatigue development and motor unit activation during the

130 The roles of muscle fatigue development and motor unit activation in determi

131 Peripheral fatigue development and motor unit activation were measu

132 uscle sensory feedback related to peripheral fatigue development are thought to restrict motor unit a

133 resulted in significantly greater peripheral fatigue development than CON (54.3 +/- 34.8%; P < 0.001)

134 between motor unit activation and peripheral fatigue development.

135 between motor unit activation and peripheral fatigue development.

136 play a comparable magnitude of diaphragmatic fatigue (DF) after work-matched inspiratory loading.

137 iated adverse events (of any grade) included fatigue, diarrhea, asthenia, nausea, and dizziness.

138 with terrestrial observations and models of fatigue-driven exfoliation and demonstrate how crack pro

139 out medical problems leading to unexplained fatigue due to a complete lack of disease-specific bioma

140 ed to the dscaml1 mutation, including severe fatigue during gaze stabilization, reduced saccade ampli

141 rofile elastic exosuit to reduce back muscle fatigue during leaning, which may improve endurance for

142 type of damage evolution, i.e., the creep or fatigue, during the operation.

143 emotional, role, and social functioning and fatigue, dyspnea, sleep, and financial problems were sev

144 r-old African American female presented with fatigue, easy bruising, and fever.

145 proprioception variables to assess the local fatigue effects of the abductor hip muscles on the funct

146 Fatiguing exercise causes hydrolysis of phosphocreatine,

147 nal modeling of choice behavior we find that fatiguing exertions cause participants to increase their

148 her yield, which significantly decreases the fatigue experienced by the system upon repeated photocyc

149 micrometer-scale deformation mechanisms with fatigue failure at the bulk scale in metals.

150 talline microstructures, which often lead to fatigue failure.

151 and long shifts can have negative effects on fatigue, family, and social life.

152 ir; however, she had continued to experience fatigue, fever, chills, abdominal bloating, and loss of

153 e of oseltamivir; however, she had continued fatigue, fever, chills, abdominal bloating, and loss of

154 ost common being hypertension (eight [13%]), fatigue (five [8%]), nausea (four [7%]), neutropenia (fo

155 profile, elastic exosuit reduced the rate of fatigue for six lumbar extensor muscles during leaning.

156 improved muscle strength, increased time-to-fatigue (for VO(2max)), reduced cortical porosity and im

157 A); diarrhoea (four [25%] of 20; cohort B); fatigue (four [22%] of 18; cohort C); and rash (five [26

158 ix [11%]), hypoalbuminaemia (six [11%]), and fatigue (four [7%]).

159 Chronic fatigue frequency decreased from 82% to 35%, for a betwe

160 p analyses of gender, ferritin < 25 ug/L and fatigue >= 4 points, as well as exploratory analyses of

161 While fatigue has the greatest impact on patient life, the imp

162 derate adverse events included hypertension, fatigue, headache, and irregular menstruation.

163 a rural facility complaining of weight-loss, fatigue, hematuria, dysuria, painful right inguinal ulce

164 ents of these nociceptive, interoceptive and fatiguing illnesses.

165 osis who reported fatigue and had a Modified Fatigue Impact Scale (MFIS) score of more than 33 were r

166 ver, there is a limited understanding of how fatigue impacts effort-based decision-making at the leve

167 d functional neuroimaging paradigm to induce fatigue in 39 healthy individuals, regressed the signal

168 tissue integrity, microglia activation, and fatigue in female mice, thus identifying a novel relatio

169 nil, or methylphenidate for the treatment of fatigue in multiple sclerosis.

170 monly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence sup

171 en compared to men, whereas the magnitude of fatigue in normoxia did not differ between sexes.

172 e Risk Management Systems to protect against fatigue in nurses, midwives, and other shift working hea

173 nterventions for mitigating lymphatic muscle fatigue in patients with dysfunctional lymphatics.

174 TA CK-2066260 effectively counteracts muscle fatigue in rodent skeletal muscle in vitro, in situ, and

175 thostatic tachycardia syndrome), and malaise/fatigue (including chronic fatigue syndrome).

176 ontal regions largely decreased as cognitive fatigue increased while connectivity between these seeds

177 y between these regions changed as cognitive fatigue increased.

178 herapy Kidney Symptom Index-19 and the Brief Fatigue Inventory.

179 Fatigue is a difficult multi-scale modelling problem nuc

180 Cold dwell fatigue is a phenomenon in titanium where stress holds a

181 Compassion fatigue is a work-related professional hazard acquired w

182 elevant protective effect of 25OHD-levels on fatigue is unlikely.

183 Overall, after 13 years, pain and fatigue levels remained significant, 5 patients were sti

184 ed into three groups according to historical fatigue levels: SF (n = 30, i.e. patients who reported f

185 ommon in a built component, hence decreasing fatigue life and mechanical strength.

186 Fatigue loading above a threshold stress is found to pro

187 She also noted a nonproductive cough, fatigue, loss of appetite, and an unintentional weight l

188 The most prevalent persistent symptoms were fatigue, loss of smell and taste, and arthralgias.

189 midwives that had evaluated a sleep-related/fatigue-management intervention; and (2) studies that re

190 The literature related to sleep-related/fatigue-management interventions for nurses and midwives

191 ddress two questions: (1) what sleep-related/fatigue-management interventions have been assessed in n

192 on the evaluation of discreet sleep-related/fatigue-management interventions.

193 hysical function (MD -15, 95% CI -24 to -7), fatigue (MD 16, 95% CI 5-26), pain (MD 18, 95% CI 7-30),

194 nnaires, Breast cancer module [QLQ-BR23] and Fatigue module [QLQ-FA12], Hospital Anxiety and Depressi

195 hly, consisting of four domain (functioning, fatigue/mood, fears/shame, nutrition) and total scores.

196 ic therapy still shows prolonged symptoms of fatigue, musculoskeletal pain, and perceived cognitive i

197 only reported grade 3 systemic symptoms were fatigue, myalgia, and chills.

198 Common side effects included fatigue, myalgia, headache, arthralgia, and fever.

199 = 15; 14.3%), asthenia (n = 14; 13.3%), and fatigue (n = 13; 12.4%).

200 adverse events were diarrhea (n = 18; 53%), fatigue (n = 16; 47%), nausea (n = 13; 38%), and decreas

201 ly (n = 142) were alopecia (n = 88 [62.0%]), fatigue (n = 78 [54.9%]), myalgia (n = 69 [48.6%]), naus

202 (n=58), neutropenia (n=31), anaemia (n=28), fatigue (n=14), hyponatraemia (n=10), and nausea (n=8).

203 clearly shows neurological symptoms, such as fatigue, nausea, and dizziness, the implications for bra

204 eemed related to capivasertib were diarrhea, fatigue, nausea, and rash.

205 most common drug-related adverse events were fatigue, nausea, diarrhea, anorexia, vomiting, periphera

206 T02042989 included anemia, thrombocytopenia, fatigue, nausea, vomiting, and diarrhea.

207 ive fatigue and that potentially comprise a "fatigue network".

208 ppeared to be central 'nodes' or hubs of the fatigue network.

209 Common grade 1 or 2 toxicities were nausea, fatigue, neutropenia, alopecia, dizziness, and dyspnea.

210 but reported fatigue previously), and never fatigued (NF, n = 37).

211 The most common AEs were headache and fatigue, occurring at similar frequencies with and witho

212 ding to progressive muscle weakness in which fatigue occurs and affects quality of life.

213 We found that, in acute hypoxia, fatigue of the diaphragm is greater in women compared to

214 s 0), infection (four [6%] vs two [3%]), and fatigue (one [1%] vs three [4%]).

215 nt adverse events were anaemia (three [7%]), fatigue (one [2%]), diarrhoea (one [2%]), decreased appe

216 ur (5%) were grade 3 or higher (two [3%] for fatigue; one [1%] each for decreased blood phosphorus an

217 come measures were hospital records of pain, fatigue, or circulatory symptoms.

218 Cognitive fatigue, or fatigue related to mental work, is a common

219 placebo in improving symptoms of depression, fatigue, or sexual dysfunction.

220 e patient suffers from chronic tiredness and fatigue, or we do treat it through blood transfusions, l

221 electrodes exhibit high transparency and low fatigue over many stretching cycles.

222 t (P = .02), head/neck discomfort (P = .03), fatigue (P = .03), and motion sickness (P = .01).

223 eceived HA-WBRT plus memantine reported less fatigue (P = .04), less difficulty with remembering thin

224 These deficits were not primarily due to fatigue; performance on the same tasks was unaffected af

225 e following 5 criteria from the FRAIL scale: fatigue, poor strength, low aerobic capacity, having >=5

226 e following 5 criteria from the FRAIL scale: fatigue, poor strength, reduced aerobic capacity, having

227 igued at the latest assessment, but reported fatigue previously), and never fatigued (NF, n = 37).

228 ngs suggest that hip abductor muscles' local fatigue produces a significant effect on a general funct

229 Pain, fatigue, quality of life, and CFS symptoms were equivale

230 ol quality-of-life questionnaire, and Pichot fatigue questionnaire.Measurements and Main Results: A t

231 six subjects showed consistent reductions in fatigue rate (ranging from 26% to 87%) for a subset of l

232 (via surface electromyography) and assessed fatigue rate via median frequency slope.

233 chomotor vigilance task (PVT) and subjective fatigue ratings.

234 ower risk of the individual frailty criteria fatigue, reduced resistance, reduced aerobic capacity, a

235 e following 5 criteria from the FRAIL scale: fatigue, reduced resistance, reduced aerobic capacity, h

236 Cognitive fatigue, or fatigue related to mental work, is a common experience.

237 crosphere dose-dependent reduction in muscle fatigue resistance (P < 0.001), despite preserved femora

238 the proportion of functional capillaries and fatigue resistance (P = 0.002).

239 improved both perfused capillary density and fatigue resistance (P<0.05), confirming that the capacit

240 Knee-extensors demonstrate greater fatigue resistance in females compared to males during s

241 We demonstrate that muscle fatigue resistance is closely coupled with functional mi

242 cal differences, females demonstrate greater fatigue resistance of locomotor muscle during single-lim

243 ogels' fracturing processes reveals that the fatigue resistance results from the crack pinning by the

244 e to muscle overload causes a restoration of fatigue resistance via angiogenic remodelling.

245 hetically well accessible and show excellent fatigue resistance.

246 ise training in skeletal muscle and promotes fatigue-resistance.

247 Such fatigue-resistant adhesion has not been achieved between

248 ydrogels on engineering materials can give a fatigue-resistant adhesion with an interfacial fatigue t

249 We further demonstrate that the fatigue-resistant hydrogel coatings exhibit low friction

250 Our method enables fatigue-resistant hydrogel coatings on diverse engineeri

251 ogression, consistent with the death of fast fatigue-resistant motor units and superior survival of s

252 nted with a view to developing comprehensive Fatigue Risk Management Systems to protect against fatig

253 other safety-critical sectors have developed Fatigue Risk Management Systems, healthcare is behind th

254 urvey, Circadian Type Inventory, and Chronic Fatigue Scale along with data regarding drowsy driving a

255 The treatment groups did not differ in fatigue score over 24 months (difference in average scor

256 The Pichot fatigue score was reduced with pitolisant.

257 8 weeks after intervention, self-rated mean fatigue scores (numeric rating scale from 1-10, primary

258 ver, porosity defects remain a challenge for fatigue-sensitive applications.

259 ight [5%]), abdominal pain (seven [5%]), and fatigue (seven [5%]).

260 Fatigue can be measured within the Fatigue Severity Scale (FSS).

261 onnaire consisting of nine items to quantify fatigue severity within the last week.

262 Secondary endpoints included fatigue, sexual function, and safety measures.

263 he most common grade 3-4 adverse events were fatigue (six [9%] patients), hypertension (five [7%]), p

264 despread musculoskeletal pain and associated fatigue, sleep disturbances, and other cognitive and som

265 tudies that reported intervention effects on fatigue, sleep, or performance at work, and on measures

266 Subjective AEs included fatigue, subjective muscular, and nervous system AEs.

267 Chronic fatigue syndrome (CFS) patients often suffer from severe

268 riterion for Gulf War Illness (GWI), Chronic Fatigue Syndrome (CFS), and fibromyalgia (FM).

269 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) involves severe fatigue, unref

270 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex chronic disease,

271 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease with no k

272 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex multisystem illne

273 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating multisystemi

274 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a highly debilitating disea

275 ome), and malaise/fatigue (including chronic fatigue syndrome).

276 n timing, duration, and magnitude during the fatigue task.

277 ng pills daily and can experience medication fatigue that might lead to suboptimal treatment adherenc

278 s, with pairings of joint pain, headache, or fatigue the most frequent.

279 tigue-resistant adhesion with an interfacial fatigue threshold of 800 J m(-2), because the fatigue-cr

280 ing symptoms that range from acute fever and fatigue to chronic fatal endocarditis.

281 lly relevant descriptions of neutropenia and fatigue trajectories caused by lenalidomide that were no

282 ease (four [5%]), hypertension (three [4%]), fatigue (two [2%]), and hypophosphataemia (two (2%]); in

283 Moreover, diabetic fatigued ulnae had more severe disruptions of osteocyte

284 ic fatigue syndrome (ME/CFS) involves severe fatigue, unrefreshing sleep, and cognitive impairment, l

285 ificant differences were found for the sleep/fatigue, urinary (large effects) and miscellaneous NMSS

286 Using the FSS, fatigue was measured in 28 adult patients, subdivided in

287 Fatigue was most closely correlated with other symptoms

288 Severe fatigue was reported by 2,008 (23.1%): 843 (19.0%) after

289 treatment-related adverse event (grade 1-4); fatigue was the most common treatment-related adverse ev

290 standard lattices have well known shear and fatigue weaknesses due to their periodic basis/structure

291 Corresponding proportions for dry mouth and fatigue were 48% and 45%, respectively.

292 Headache, nausea, and fatigue were also more common among patients receiving o

293 rade >= 3 anemia, dehydration, diarrhea, and fatigue were greater in patients with IT.

294 cities (DLTs; grade 3 arthralgia and grade 3 fatigue) were reported in the initial dose level (lenvat

295 The most frequent adverse event was fatigue with a pooled prevalence of 16% (95% CI 5-29%),

296 Shift work interferes with sleep and causes fatigue with adverse effects for nurses' and midwives' h

297 ing shift work-related sleep restriction and fatigue with errors, accidents, and adverse long-term he

298 e at 40% of maximal voluntary contraction to fatigue with postexercise circulatory arrest for 2 minut

299 ith pembrolizumab (in 33 [13%] patients) and fatigue with standard of care (in 43 [18%]).

300 g, or hurting of the treated breast, and (3) fatigue within 7 days of completing whole-breast radioth